Key Points:
Bidi Vapor LLC urges the Eleventh Circuit Court of Appeals to overturn the FDA's decision to reject its disposable e-cigarette application, arguing that the decision is unlawful.
The FDA rejected Bidi's application for its tobacco-flavored disposable e-cigarette, citing a lack of evidence demonstrating overall net benefit and insufficient evidence to address health risks.
In August 2022, Bidi Vapor successfully overturned the FDA's Marketing Denial Orders（MDO） for its 10 non-tobacco flavored products, allowing them to re-enter the scientific review phase and continue sales.
According to a recent report by Tobacco Reporter, Bidi Vapor LLC is urging the Eleventh Circuit Court of Appeals to overturn the decision by the U.S. Food and Drug Administration (FDA) to reject its application to sell disposable e-cigarettes, claiming that the agency's actions are illegal.
During the oral debate in Miami, lawyer Eric Gotting told the appeals panel that the FDA's decision was "arbitrary and capricious, and illegal." He pointed out that the agency acknowledged that adult smokers might switch to using Bidi's safer disposable e-cigarette product - an e-cigarette pre-filled with tobacco-flavored e-liquid, but still rejected Bidi's application.
In January 2024, the FDA issued a Market Denial Order (MDO) for the tobacco-flavored Bidi Stick-Classic disposable e-cigarette. This decision came as the agency continued to seek a second review of market applications for other flavored products from Bidi Vapor. The FDA stated that Bidi's premarket tobacco application "failed to demonstrate a net benefit to overall tobacco product users and lacked sufficient evidence to address health risks.
Bidi believes that the FDA violated the Administrative Procedure Act and is hopeful to establish a basis for challenging unfavorable decisions by the agency, as it has done successfully in the past. In August 2022, the Eleventh Circuit Court of Appeals overturned the market denial order (MDO) for its 10 non-tobacco flavored products. This decision has allowed these 10 PMTAs (premarket tobacco product applications) to undergo scientific review again and permits the sale of these flavors to continue under the FDA's tobacco product compliance policy.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
